MEK and CDK4/6 Inhibitor Combination Therapy for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is aggressive and difficult to treat due to its desmoplastic response, hypovascularity, poor drug delivery, and resistance to chemotherapy and immunotherapy, leading to a dire prognosis with limited effective treatment options.
Innovation Solution
A combination therapy using a MEK inhibitor and a CDK4/6 inhibitor, such as trametinib and palbociclib, which induces cellular senescence and senescence-associated secretory phenotype (SASP) in pancreatic cancer cells, promoting vascular re-normalization and increasing drug permeability, thereby enhancing the efficacy of cytotoxic agents and immunotherapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pancreatic cancer is treated with conventional chemotherapy or immunotherapy, then treatment is administered, but the therapy is ineffective due to drug delivery barriers and tumor resistance
Solution Approach 1:
The patent applies preliminary action by using MEK and CDK4/6 inhibitors to induce cellular senescence and SASP phenotype in pancreatic cancer cells before administering conventional chemotherapy or immunotherapy. This preliminary treatment modifies the tumor microenvironment to improve subsequent drug delivery and immune cell infiltration, thereby overcoming the initial resistance barriers.
Solution Approach 2:
The patent changes the physiological parameters of the tumor microenvironment by inducing senescence-associated secretory phenotype (SASP) through dual inhibition of MEK and CDK4/6 pathways. This parameter change involves altering the secretory profile of cancer cells to produce factors that normalize vasculature and enhance immune cell recruitment, thereby improving treatment efficacy.
2Reliability
If MEK inhibitor and CDK4/6 inhibitor combination therapy is administered, then treatment efficacy is improved through SASP induction, but the mechanism requires complex dual pathway inhibition
Solution Approach 1:
The patent merges two distinct therapeutic agents (MEK inhibitor and CDK4/6 inhibitor) into a combination regimen that targets two different signaling pathways simultaneously. This merging approach synergistically induces SASP phenotype more effectively than single-agent therapy, despite the increased mechanistic complexity.
Solution Approach 2:
The combination therapy exhibits multi-functionality by simultaneously achieving multiple therapeutic effects: inducing cellular senescence, normalizing tumor vasculature, enhancing immune cell infiltration, and improving drug delivery. This universal approach addresses multiple aspects of tumor pathology through a single treatment regimen.
3Productivity
If conventional monotherapy is used, then treatment simplicity is maintained, but clinical outcomes are poor due to tumor aggressiveness and resistance
Solution Approach 1:
The patent employs preliminary action by administering MEK and CDK4/6 inhibitors before conventional chemotherapy or immunotherapy to prime the tumor microenvironment. This sequential approach improves subsequent treatment efficacy while maintaining a manageable treatment structure through staged administration.
Data Source
AI summary
The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.